Oral Factor D Inhibitor Fails to Improve Myasthenia Gravis Symptoms

Generalized myasthenia gravis remains a complex autoimmune challenge characterized by fluctuating skeletal muscle weakness and the potential for life-threatening respiratory failure [1]. While traditional management relies on corticosteroids and broad immunosuppressants, therapeutic focus has recently shifted toward targeting the complement cascade, which drives postsynaptic membrane damage at the neuromuscular junction [2, 3]. Currently approved terminal complement inhibitors have demonstrated efficacy in refractory cases, yet these agents require intravenous or subcutaneous administration and carry a well-documented risk of meningococcal infection [4, 5]. Researchers have hypothesized that inhibiting the alternative complement pathway might preserve baseline immune function while offering the convenience of oral dosing [6, 7]. A recent multicenter trial investigated whether this strategy could provide a viable, safer alternative to existing biologics for daily clinical practice.